With expansion of production capacity, range of services, and customer base, CMC continues to grow. Earlier this year, CMC acquired the former ICOS Biologics development and manufacturing facility in Seattle, WA, from Eli Lilly. Now known as CMC ICOS Biologics, this facility focuses primarily on mammalian production, and during 2008 it is being upgraded to enable production of in-market biopharmaceuticals as well as late-stage clinical trial material. Dr. Gustavo Mahler, previously with Bayer Healthcare, has been appointed president of CMC ICOS. With this acquisition, CMC has significantly increased its production facilities as well as added additional services including formulation and cell line development. With facilities in both the United States and Europe — and many satisfied customers on both continents — CMC has become one of the world’s largest biopharmaceutical contract manufacturers. With the acquisition of ICOS Biologics, CMC acquired the rights to the CHO cell line expression technology, CHEF1®. This proprietary technology rapidly creates cell lines capable of producing high yields, even of complex glycoproteins, and allows clients’ cell line development to be fast tracked.

In summary, CMC offers production from both mammalian and microbial systems, from process development to in-market supply, up to 3,000 L capacity. The design of both facilities allows for capacity and technological flexibility while ensuring compliance with strict pharmaceutical regulations required for CGMP up to and including manufacturing of licensed products. Whether our clients choose our Copenhagen facility in Denmark or our Seattle facility in the United States, they are assured of benefiting from over 15 years of biologics process development, technical transfer, and CGMP manufacturing expertise. At both facilities, all divisions are dedicated to the successful completion of each project and to meeting the goals of each client.

Cell culture facilities ()

Cell culture facilities include CGMP cell banking and culture expansion facilities; four cell culture development laboratories designed as cleanrooms; a 130-L cell culture pilot plant (non-GMP); and CGMP manufacturing lines with batch, fed-batch, and continuous operation capacities ranging from 130 L to 2,000 L and perfusion capacity up to 1,000 L/day.

Microbial facilities ()